RATIONALE AND OBJECTIVES: Gadolinium III texaphyrin (Gd[III] texaphyrin) complex, a new magnetic resonance imaging contrast (MRI) agent, was evaluated. METHODS: In vitro relaxivity (1.5 T) and stability studies (5% dextrose) were conducted. Subchronic toxicity (8 males, 8 females; 2-20 mumol Gd(III) texaphyrin complex/kg body weight; 3 times per week for 3 weeks). Biodistribution and excretion studies were conducted in Sprague-Dawley rats; MRI studies were conducted in normal and tumor-bearing rats and rabbits. RESULTS: Relaxivity values were as follows: r1 = 19 (mumol/L.sec)-1 and r2 = 22 (mumol/L.sec)-1. The 21-day subchronic toxicity study revealed no abnormalities. The compound is stable. Biodistribution demonstrated liver uptake. Magnetic resonance imaging in normal (n = 34) and tumor-bearing (n = 4) rats and normal (n = 8) and tumor-bearing (n = 19) rabbits revealed: significant (P < .05) contrast enhancement of liver and kidney after 1-17 mumol/kg of Gd(III) texaphyrin complex. Gadolinium (III) texaphyrin complex (2.5 mumol/kg) produced significant contrast enhancement of liver carcinomas in rabbits (n = 8). Thigh V2 carcinomas (n = 22) had selective (P < .05) enhancement, 5 mumol/kg. In rat fibrosarcomas (n = 4), 17 mumol Gd(III) texaphyrin complex produced significant enhancement up to 24 hours. CONCLUSIONS: Gadolinium (III) texaphyrin complex appears to be an effective and safe MRI contrast agent.
RATIONALE AND OBJECTIVES:Gadolinium III texaphyrin (Gd[III] texaphyrin) complex, a new magnetic resonance imaging contrast (MRI) agent, was evaluated. METHODS: In vitro relaxivity (1.5 T) and stability studies (5% dextrose) were conducted. Subchronic toxicity (8 males, 8 females; 2-20 mumol Gd(III) texaphyrin complex/kg body weight; 3 times per week for 3 weeks). Biodistribution and excretion studies were conducted in Sprague-Dawley rats; MRI studies were conducted in normal and tumor-bearing rats and rabbits. RESULTS: Relaxivity values were as follows: r1 = 19 (mumol/L.sec)-1 and r2 = 22 (mumol/L.sec)-1. The 21-day subchronic toxicity study revealed no abnormalities. The compound is stable. Biodistribution demonstrated liver uptake. Magnetic resonance imaging in normal (n = 34) and tumor-bearing (n = 4) rats and normal (n = 8) and tumor-bearing (n = 19) rabbits revealed: significant (P < .05) contrast enhancement of liver and kidney after 1-17 mumol/kg of Gd(III) texaphyrin complex. Gadolinium (III) texaphyrin complex (2.5 mumol/kg) produced significant contrast enhancement of liver carcinomas in rabbits (n = 8). Thigh V2 carcinomas (n = 22) had selective (P < .05) enhancement, 5 mumol/kg. In ratfibrosarcomas (n = 4), 17 mumol Gd(III) texaphyrin complex produced significant enhancement up to 24 hours. CONCLUSIONS:Gadolinium (III) texaphyrin complex appears to be an effective and safe MRI contrast agent.
Authors: S W Young; F Qing; A Harriman; J L Sessler; W C Dow; T D Mody; G W Hemmi; Y Hao; R A Miller Journal: Proc Natl Acad Sci U S A Date: 1996-06-25 Impact factor: 11.205
Authors: Adam M Sonabend; R Morgan Stuart; Jonathan Yun; Ted Yanagihara; Hamed Mohajed; Steven Dashnaw; Samuel S Bruce; Truman Brown; Alex Romanov; Manu Sebastian; Fernando Arias-Mendoza; Emilia Bagiella; Peter Canoll; Jeffrey N Bruce Journal: Neuro Oncol Date: 2011-07-12 Impact factor: 12.300
Authors: Jonathan F Arambula; Jonathan L Sessler; Mark E Fountain; Wen-hao Wei; Darren Magda; Zahid H Siddik Journal: Dalton Trans Date: 2009-10-07 Impact factor: 4.390
Authors: Heike E Daldrup-Link; Martina Rudelius; Stephan Metz; Guido Piontek; Bernd Pichler; Marcus Settles; Ulrich Heinzmann; Jürgen Schlegel; Robert A J Oostendorp; Ernst J Rummeny Journal: Eur J Nucl Med Mol Imaging Date: 2004-05-11 Impact factor: 9.236